HOW TO IMPROVE THE RISK-BENEFIT RATIO OF ANTIDEPRESSANTS

被引：8

作者：

CORRUBLE, E ^{[1
]}

PUECH, AJ ^{[1
]}

机构：

[1] GRP HOSP PITIE SALPETRIERE,SERV PHARMACOL,F-75651 PARIS 13,FRANCE

来源：

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY | 1993年 / 8卷 / 04期

关键词：

ANTIDEPRESSANTS; BENEFITS; IMPROVEMENT; RISKS;

D O I：

10.1097/00004850-199300840-00005

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

To improve the risk associated with present antidepressant drugs, it is necessary to choose drugs that are selective and well tolerated in overdose, to look for contraindications, to adapt the dose progressively, to inform and supervise patients adequately, and to deal with risks due to the main pharmacological effects (anxiety, nervousness, sleep disturbances, suicide). With new drugs, risk improvement will probably be the result of greater selectivity. Improvements in efficacy could emerge during the development of new drugs, based on the monoaminergic and non-monoaminergic hypotheses. Much progress could be made, however, by questioning present practices. Optimizing dose, duration of treatment, co-medication, strategies for non-responders, and compliance, decreasing onset of action and targeting patients may help improve the efficacy of present antidepressant drugs.

引用

页码：237 / 241

页数：5